

Estrogen receptor β transcript variants associate with oncogene expression in endometrial cancer

JULIA HÄRING^{1*}, MACIEJ SKRZYPCZAK^{1,3*}, ANETTE STEGERER¹, CLAUS LATTRICH¹,
FLORIAN WEBER², REGINA GÖRSE¹, OLAF ORTMANN¹ and OLIVER TREECK¹

Departments of ¹Obstetrics and Gynecology, and ²Pathology, University Medical Center Regensburg, Regensburg, Germany; ³Second Department of Gynecology, Medical University of Lublin, Poland

Received December 9, 2011; Accepted January 30, 2012

DOI: 10.3892/ijmm.2012.929

Abstract. The human ESR2 gene codes for estrogen receptor β 1 and for multiple splice variants, which are suggested to exert distinct functions in the cellular estrogen response. Given that the function of ER β in endometrial cancer remains unclear, we examined the expression of ER β 1, ER β 2 and various further ER β transcript variants and their association with selected cancer-related genes in 74 human endometrium samples and endometrial cancer specimens by means of RT-qPCR. Additionally, we knocked down ER β expression in HEC-1A endometrial adenocarcinoma cells by means of siRNA transfection. Expression of four ER β transcript variants was significantly elevated in cancer tissue or in G3 tumors compared to postmenopausal endometrium. Expression of ER β 1, ER β 2, ER β 5 and five further variants was associated with the oncogenes MYBL2 or HER2 in endometrial cancer. In addition, siRNA-triggered knockdown of ER β expression led to a significant decline of MYBL2 mRNA and protein levels in endometrial cancer cells. Our observation of increased ER β transcript levels in cancer tissue and particularly their correlation with the expression of oncogenes, as well as the results of our knockdown studies, suggest a role of ER β in endometrial carcinogenesis.

Introduction

Endometrial cancer is known to be a hormone-dependent neoplasia which is caused by a stepwise accumulation of molecular alterations in cellular pathways regarding proliferation and differentiation. Expression of steroid hormone receptors like estrogen receptors (ER) α and β and progesterone

receptor (PR) plays an important role in regulation of normal endometrial function. Changes of the ER and PR expression patterns may play an important role in the pathogenesis of endometrial cancer. Loss of steroid receptors during tumorigenesis is often associated with an aggressive clinical course and a poorer survival in endometrial cancer patients. Whereas ER α is thought to primarily mediate the proliferative effect of estrogens in endometrial tissue, the function of ER β in this tissue remains unclear. In other hormone-dependent tissues like the breast, ER β is known to exert antagonistic effects on ER α action, resulting for example in reduction of cellular proliferation. The growth inhibitory action of ER β and the observed decline of ER β expression during carcinogenesis have raised the hypothesis that this receptor may act as a tumor suppressor in hormone-dependent tissues like the breast or prostate (1-3).

The ER β gene (ESR2) codes for a multitude of different transcripts resulting from alternative splicing. The ER β splice variants 1, 2 and 5 are characterized by a specific C-terminal region coded by ESR2 exon 8, whereas other ER β splice variants result from exon skipping. Previous studies clearly suggested that ER β variants differ in their ability to bind to ligands, DNA or cofactors, and thus exert distinct functions and have a specific significance in hormone-dependent cancer (4,5).

Recent studies have revealed that molecular alterations such as oncogene activation and tumor suppressor inactivation are characteristic steps during endometrial carcinogenesis. Loss or mutation of tumor suppressor PTEN is seen in up to 80% of endometrioid tumors, whereas overexpression of HER2 receptor tyrosine kinase is present in about 60% of endometrial adenocarcinoma (6). Another molecular alteration in endometrial cancer is overexpression of growth promoting genes like cyclins, which is associated with an undifferentiated phenotype and an unfavorable prognosis (7).

In the present study, we further evaluated the function of ER β , represented by its most frequent variants ER β 1, 2 and 5 and various exon-skipped isoforms, in endometrial cancer. For this purpose, we compared expression of these ER β variants and of two oncogenes in normal and malignant tissues. Because no antibodies were available for the 15 exon-skipped ER β isoforms tested, this study had to be performed at the mRNA level by means of RT-qPCR.

Correspondence to: Dr Oliver Treeck, Department of Obstetrics and Gynecology, University Medical Center Regensburg, Landshuter Str. 65, D-93053 Regensburg, Germany
E-mail: otreeck@caritasstjosef.de

*Contributed equally

Key words: estrogen receptor β , alternative splicing, endometrial cancer

Patients and methods

Patients. In this study, we examined a total of 74 endometrial samples including 28 samples from normal endometrium and 46 cases of endometrioid endometrial carcinoma. The endometrial tissue specimens were collected between 2007 and 2009 by the Second Department of Gynecology of the Medical University of Lublin, Poland and by the Clinic of Obstetrics and Gynecology, Medical University of Regensburg, Germany. From the 11 premenopausal patients, aged 43-53 years, 5 were in the proliferative phase and 6 in the secretory phase of the menstrual cycle. The 17 postmenopausal women were aged between 46 and 90 years. Normal endometrial tissue was obtained from women subjected to surgery for reasons other than pathology of the endometrium, mainly cervical cancer. The group of endometrial cancer patients (endometrioid subtype), ranging from 54 to 82 years of age, underwent curative resection and could be divided into grading subgroups (G1, 15 cases; G2, 16 cases; G3, 15 cases). Informed consent for their participation in the studies was obtained from all patients. Tissue samples of patients were collected in accordance with German or Polish regulations and in agreement with the Ethics Committees of the University School of Medicine in Lublin, Poland or the Medical University of Regensburg, Germany. Complete clinical data were available for every patient. Immediately following surgery, tissues were stored in liquid nitrogen until RNA extraction.

Materials. DMEM/F12 culture medium was obtained from Invitrogen (Karlsruhe, Germany) and FCS was purchased from PAA (Pasching, Austria). HEC-1A endometrial adenocarcinoma cells were obtained from the American Type Culture Collection (Manassas, VA, USA). M-MLV-P reverse transcriptase was purchased from Promega (Mannheim, Germany). RNeasy mini kit, RNase-free DNase Set and the QuantiTect SYBR-Green PCR kit were obtained from Qiagen (Hilden, Germany). PCR primers were synthesized at Metabion (Planegg-Martinsried, Germany). The transfectin reagent was obtained from Bio-Rad (Hercules, CA, USA). Platinum Pfx polymerase and OptiMEM medium were purchased from Invitrogen. ER β siRNAs were from Ambion (Austin, TX, USA). Serum replacement 2 (SR2) was from Sigma (Deisenhofen, Germany).

Cell culture and cell proliferation assay. HEC-1A and HEC-1B endometrial adenocarcinoma cells obtained from the American Type Culture Collection were maintained in phenol red-free DMEM/F12 medium supplemented with 10% FCS or with 1X serum replacement 2 (SR2, Sigma). Cells were cultured with 5% CO₂ at 37°C in a humidified incubator. Cells were seeded in 96-well plates (MDA-MB-231 200 cells/well; BT-474 800 cells/well; SK-BR-3 800 cells/well). The next day cells were treated with the GPR30 agonist G-1 (10, 100 nM or 1 μ M), herceptin (10 μ g/ml) or the combinations of both agents in triplicate. On Days 0, 3 and 5 relative numbers of viable cells were measured in comparison to solvent controls by means of the fluorimetric, resazurin-based CellTiter-Blue assay (Promega) according to the manufacturer's instructions at 560Ex/590Em nm in a Victor3 multilabel counter (Perkin-Elmer, Germany). Cell growth was expressed either

as percentage of Day 0 or as percentage of the solvent controls. For statistical analysis we performed a two-way ANOVA analysis and Bonferroni post-tests, using the GraphPad Prism Version 5.01 Software (GraphPad Software, San Diego, CA, USA). We considered data as significant at $P < 0.05$.

Transient transfection assay. HEC-1A cells (4×10^5 per well) were seeded in DMEM/F12 containing 10% FCS in a 6-well dish. After 24 h, cells were transfected with 300 nM siRNA in OptiMEM reduced serum medium using 8 μ l of Transfectin reagent (Bio-Rad). For knockdown of ER β expression, we used an equimolar mixture of three different pre-designed Silencer siRNAs (#4148, #202031 and #145911; Ambion) targeting different regions of ER β mRNA. The siRNA sense sequences (5'→3') were GGAAUUCUGGAAAUCUUUGtt, GCAUUCAAGGACAUAAUGAtt and CCUUACCUGU AACAGAGAtt, respectively. As a negative control siRNA verified to not interact with any human RNA, the Silencer Negative Control #1 siRNA (AM4611, Ambion) was used. At 3-4 days after siRNA treatment, cells were harvested and total-RNA was isolated.

RNA preparation and real-time RT-PCR. Total-RNA from endometrial tissue samples was isolated from 30 to 80 mg frozen tissue using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. RNA purity and concentration was analyzed by spectrophotometry. From each sample, 300 ng of total-RNA was reverse transcribed to cDNA using 40 units of M-MLV reverse transcriptase and RNasin (Promega) with 80 ng/ μ l random hexamer primers (Invitrogen) and 10 mM dNTP mixture (Fermentas, St. Leon-Rot, Germany) according to the manufacturer's instructions. After reverse transcription, the mRNA levels of ER β variants and marker genes were determined by real-time PCR. For this purpose, 4 μ l of cDNA were amplified using the LightCycler[®] FastStart DNA Master^{PLUS} SYBR-Green I (Roche Diagnostics GmbH, Mannheim, Germany) and 5 mM of each primer (Table I). Oligonucleotides (Metabion, Planegg-Martinsried, Germany) were designed to be intron-spanning to avoid genomic contaminations.

Real-time PCRs were carried out in a LightCycler[®] 1.0 Instrument (Roche) under the following conditions: initial denaturation at 95°C for 15 min, followed by 45 cycles with 10 sec denaturation at 95°C, 5 sec annealing at 60°C and 12 sec extension at 72°C. The PCR program was completed by a standard melting curve analysis. Negative controls were prepared by adding distilled water instead of cDNA. To verify the identity of the PCR products, they were also analyzed by electrophoresis in 1.5% agarose gels and stained with ethidium bromide. After size check, each PCR product was then purified using the QIAquick Gel Extraction kit (Qiagen), following the manufacturer's protocol and verified by sequencing (Eurofins MWG Operon, Ebersberg, Germany). Generally, PCR primers were designed to be intron-spanning. In all RT-PCR experiments, a 190 bp β -actin fragment was amplified as a reference gene using the intron-spanning primers actin-2573 and actin-2876. Data were analyzed using the comparative $\Delta\Delta C_T$ method (8) calculating the difference between the threshold cycle (C_T) values of the target and reference gene of each sample and then comparing the resulting ΔC_T values between different samples.

Table I. PCR primer sequences used for qPCR.

Target/splice variant	Primer (5'→3')	Amplicon (bp)
ERβ1	GGCATGCGAGTAACAAGGGC GGGAGCCCTCTTTGCTTTT	177
ERβ2	GTTTGGGTGATTGCCAAGAG TCTGCCCTCGCATG	101
ERβ5	GTTTGGGTGATTGCCAAGAG CGTACCTCGCATGCCTGA	146
ERβΔ1	TGGTTCTGAAGAGAGACACTGA CTTCACACGACCAGACTCCA	151
ERβΔ2	ACCACAAGCCCAAATGTGTT ATCATTATGTCCTGTTACAGGTAAG	157
ERβΔ3	TCAAGGCTCCCGGAGAGAG CAGGAGGGTGAGCACTAGC	172
ERβΔ4	TTTGTCCAGCTACAAATCAGTG TCCACAAAGCCCACTTCAC	112
ERβΔ6	TTCTGGACAGGTATGTACCCTCTG GGGACAGGAGCATCAGGAG	175
ERβΔ1/2 (0K)	AATATGGTTCTGAAGGACATAATGA CTTCACCATTCCCCTTCGT	128
ERβΔ1/2 (0N)	CTCGCTTTCCCTCAACAGGTG CATTATGTCCTTGCAGATAAACAC	122
ERβΔ2/3	AAACAGGCTCCCGGAGAGAG CTCCAGGAGGGTGAGCACTA	176
ERβΔ3/4	AGCATTCAAGGCTTTGTGGA CCAGAACAAGATCTGGAGCA	145
ERβΔ4/5	AAGTGTGGGATGAGGGGAAA GATCATGGCCTTGACACAGA	128
ERβΔ1/2/3 (0K)	CTGAAGGCTCCCGGAGAGAG CTCCAGGAGGGTGAGCACTA	176
ERβΔ1/2/3 (0N)	CTCGCTTTCCCTCAACAGGTG CGGGAGCCTTGCAGATAAAC	120
ERβΔ3/4/5	ATTCAAGGGATGAGGGGAAA GATCATGGCCTTGACACAGA	128
ERβΔ4/5/6	AAGTGTGGTATGTACCCTCTGG GACAGGAGCATCAGGAGGTT	170
ERα	CACATGAGTAACAAAGGCATGG ATGAAGTAGAGCCCAGTG	181
PR	CAACTACCTGAGGCCGGATT CATTGCCCTCTTAAAGAAGACCT	160
MYBL2	GGAAGACCAAAAAGTCATCGAG CTCAGGGTTGAGGTGGTTGT	130
HER2	CATGGTCAAATGTTGGATGATT CCTCATTCTGGATGACCACA	116

Antibodies and western blot analysis. HEC-1A endometrial adenocarcinoma cells were lysed in RIPA buffer [(1% (v/v) Igepal CA-630, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulphate (SDS) in phosphate-buffered solution (PBS) containing aprotinin and sodium orthovana-

date]. Aliquots containing 15 μg of protein were resolved by 10% (w/v) SDS-polyacrylamide gel electrophoresis, followed by electrotransfer to a PVDF Hybond (Amersham, Buckinghamshire, UK) membrane. Immunodetection was carried out using monoclonal MYBL2 (M02) antibody (clone




Figure 1. ER β expression in postmenopausal endometrium and in endometrioid endometrial carcinoma as assessed by RT-qPCR-based relative quantification of the indicated ER β splice variants. *Significant differences vs. the postmenopausal endometrium.

1C7, antikörper-online.de, Germany) or β -actin antibody (8226, Abcam, Germany) diluted 1:5,000 in PBS containing 5% skim milk (w/v) followed by horseradish peroxidase-conjugated secondary antibody which was detected using a chemiluminescence (ECL) system (Amersham).

Statistical analysis. Statistical analysis of the data was carried out using the InStat software (GraphPad Software). The statistical significance of the molecular gene expression changes in the endometrial carcinoma and the normal endometrium control group was assessed using the nonparametric Mann-Whitney test. Furthermore, we compared the gene expression of separate subgroups (G1, G2, G3) with the nonparametric Mann-Whitney test. The Spearman's rank correlation was used to evaluate the correlation between the expressions of two target genes. P-values < 0.05 were considered statistically significant.

Results

Differential gene expression in human endometrium and endometrial cancer. We analyzed expression of ER β 1, ER β 2, ER β 5, the further exon-skipped ER β -isoforms, ER α , PR, and the cancer-related genes MYBL2, PTEN, Cyclin A2, Cyclin B1, Cyclin D1 and HER2 in a total of 74 endometrial tissue samples by means of RT-qPCR.

Transcript levels of ER β 1 and 2 did not differ between the cancer- and the control group (Fig. 1) or between the grading subgroups (data not shown). Expression of ER β 5 was about 3-fold elevated in endometrioid endometrial cancer, particularly in the G3 subgroup when compared to the postmenopausal endometrium (P < 0.01) (Fig. 2). The exon-skipped splice variant ER β Δ 1, transcribed from the 0N promoter of ESR2 gene, also was 3-fold elevated in endometrial cancer (P < 0.01) (Fig. 1), particularly in the G1 and G2 subgroup




Figure 2. Expression of the indicated estrogen receptor transcripts in postmenopausal endometrium and in G1, G2 and G3 graded endometrial carcinoma. Data were assessed at the mRNA level by means of RT-qPCR. *P<0.01 vs. postmenopausal endometrium.

(Fig. 2). Increased transcript levels in cancer tissue were also detected analyzing the exon-skipped isoform ERβΔ2/3 (P<0.05) (Fig. 1).

In contrast, mRNA levels of the exon-deletion variant ERβΔ4 were significantly, about 3-fold decreased in endometrial cancer tissue (P<0.0001). Particularly the G2 and G3 subgroup exhibited a lower expression of this variant when compared to postmenopausal endometrium (both P<0.001). Expression of the other ERβ splice variants tested did not significantly differ between the compared groups or subgroups.

When we analyzed ERα transcript levels for comparison, we did not observe a difference between the cancer and the control group, but a significantly smaller expression was noted in the G3 subgroup compared to the normal endometrium (P<0.01) or the G1 (P<0.001) or G2 tumors (P<0.05).

Analysis of the ERβ/ERα ratio revealed a significant increase in G3 tumors when compared to the postmenopausal endometrium. This was true for the ratios ERβ1/ERα, ERβ2/ERα (both P<0.01) and particularly for the ERβ5/ERα ratio (P<0.001) (Fig. 3).

Our data also revealed differences in the expression patterns of cancer-related genes. Expression of the oncogene MYBL2 was about 4.5-fold higher in endometrial cancer than in pre- or postmenopausal endometrium (P<0.0001) (Fig. 4). We observed this significant increase of MYBL2 expression in all grading subgroups (P<0.0001). The cell cycle gene cyclin B1 exhibited a 3.9-fold elevated expression in endometrial cancer tissue compared to normal endometrium (P<0.001) (Fig. 4), particularly in G2 tumors (P<0.01) and G3 tumors (P<0.0001). Cyclin D1 was 4-fold elevated in the cancer group (P<0.001), whereas cyclin A2 mRNA levels were doubled in endometrial




Figure 3. Ratio between expression of ER β splice variants 1, 2 or 5 and ER α transcripts in postmenopausal endometrium and in G1, G2 and G3 graded endometrial carcinoma as assessed per means of *RT-qPCR*. * $P < 0.01$ vs. postmenopausal endometrium; *** $P < 0.001$ vs. postmenopausal endometrium.

tumors ($P < 0.001$) (Fig. 4) and particularly were elevated in the G3 subgroup (data not shown). As expected, expression of the tumor suppressor PTEN was reduced in endometrial cancer tissue ($P < 0.05$) (Fig. 4), however, loss of PTEN expression did not differ between the grading subgroups (data not shown). In comparison to postmenopausal endometrium, slightly higher HER2 transcript levels were detected in the cancer group ($P < 0.05$) (Fig. 4).

Association of ER β 1 and its splice variants with oncogenes and cancer related genes. To examine the potential significance of ER β expression in endometrioid endometrial cancer, we first correlated the levels of ER β 1 and its variants with expression of ER α , PR and other cancer-related genes and oncogenes using the nonparametric Spearman test.

First, this test showed the expected strong positive correlation of ER α transcript levels with PR expression ($\rho = 0.55$, $P < 0.0001$). Expression of ER β 1 and ER β 2 was strongly associated ($\rho = 0.79$) and also correlated with transcript levels of ER α ($\rho = 0.38$), but not PR. In contrast, ER β 5 expression was

Table II. Correlation of ER β splice variant expression with the indicated genes in endometrial cancer, as indicated by the Spearman's rank correlation coefficient (ρ), corrected for ties.

	MYBL2	HER2
ER β 1	-	0.310 ^a
ER β 2	-	0.308 ^a
ER β 5	0.350 ^a	-
ER β Δ 1	0.415 ^a	0.337 ^a
ER β Δ 3	0.500 ^a	0.501 ^a
ER β Δ 2/3	0.536 ^a	0.477 ^a
ER β Δ 1/2/3 (OK)	0.488 ^a	0.431 ^a
ER β Δ 1/2/3 (ON)	0.411 ^a	0.400 ^a

^aConsidered to be significant with $P < 0.001$ to $P < 0.0001$ (multiple comparison testing). -, no significant correlation observed; 0N, transcribed from the 0N promoter of the ESR2 gene; 0K, transcribed from the 0K promoter of the ESR2 gene; ER β Δ , splice variant with the indicated exon deletion but undefined exon 8.

weakly associated with ER β 2 expression ($\rho = 0.36$), but not with ER α or ER β 1 (data not shown).

Transcript levels of ER β 1 and 2 were found to be associated with the expression of the HER2 oncogene at the mRNA level. Additionally, 5 exon-deleted ER β variants were observed to positively correlate with HER2 transcript levels (Table II). The expression of ER β 5 mRNA and of five exon-skipped variants was associated with the transcript levels of the oncogene MYBL2 (Table II).

Expression of ER β Δ 1, Δ 3 and Δ 2/3 variants was associated with cyclin D1 mRNA levels, whereas ER β Δ 3, Δ 2/3 and Δ 1/2/3 (OK, transcribed from the 0K promoter of ESR2 gene), positively correlated with cyclin B1 expression ($P < 0.01$, data not shown).

Knockdown of ER β expression in HEC-1A endometrial adenocarcinoma cells. To examine the functional significance of the observed correlation between ER β and expression of oncogenes, we then knocked down expression of ER β by means of transient siRNA transfection in the endometrial adenocarcinoma cell line HEC-1A. Three days after transfection with ER β -specific siRNAs, a maximum suppression of total ER β transcript levels by about 72% was observed. In these cells, we also observed downregulation of MYBL2 mRNA by about 60%. When we performed an additional western blot analysis of MYBL2 protein expression, we also observed downregulation of this gene in HEC-1A cells treated with ER β siRNA (Fig. 5). In contrast, HER2 expression was not altered after knockdown of ER β , at the mRNA or at the protein level (data not shown).

Discussion

Estrogens have been shown to play a significant role in endometrial physiology and tumorigenesis (9). Both ERs are expressed in normal endometrium, but levels of ER β have been reported to be lower than those of ER α (10-12).




Figure 4. Expression of the indicated genes in postmenopausal endometrium and in endometrial carcinoma. Data were assessed at the mRNA level by means of RT-qPCR. *P<0.05 and ***P<0.001 vs. postmenopausal endometrium.

ER α is thought to primarily mediate the proliferative effect of estrogens both in cyclic endometrium and in pathogenesis of endometrial proliferative diseases, but the function of ER β in this tissue is not quite clear (13). Particularly the role of ER β , coded by the human ESR2 gene, in endometrial carcinogenesis remains nebulous. The ESR2 gene codes for the estrogen receptor β 1 and for multiple splice variants resulting from alternative exon usage or exon skipping, which are able to exert different functions in the cellular estrogen response (1,5,14). Thus, to elucidate the whole picture of ER β action in endometrial cancer, we decided to examine expression of all relevant ER β transcript variants.

Estrogen receptor β previously has been suggested to act as a tumor suppressor in endocrine responsive tissues like the breast and prostate (14-16). This hypothesis primarily arose from the observed decline of ER β expression in cancer tissue and from *in vitro* data demonstrating a growth-inhibitory action of this receptor (17-19). Whereas some studies supported the idea that

ER β might also act as a tumor-suppressor in the endometrium, primarily due to observation of decreased receptor levels in cancer tissue (20-22), other studies did not (22-26).

The results of our study do not suggest the presence of an antitumoral effect of ER β 1 or of its splice variants in human endometrium. Transcript levels of 18 ER β variants tested were found to be unchanged or even elevated in endometroid endometrial carcinoma. From these ER β variants, four were significantly overexpressed in endometrial cancer or in G3 tumors. Eight ER β isoforms were positively correlated with the expression of the oncogenes MYBL2 or HER2 and six associated with the cyclins B1 or D1. Supporting the results of our correlation study, and establishing a direct functional connection between ER β and MYBL2, knockdown of ER β in HEC-1A endometrial adenocarcinoma cells by means of RNAi led to downregulation of MYBL2 in this cell line. Only one ER β isoform, ER β Δ 4, was decreased in cancer tissue. Though being limited by the fact that we had to perform this study at




Figure 5. RNAi-mediated knockdown of ER β expression in HEC-1A endometrial adenocarcinoma cells decreases MYBL2 expression both at the mRNA and the protein level. Data were obtained by means of RT-qPCR (upper panels) or by western blot analysis as described in Materials and methods.

the mRNA level because no specific antibodies existed for the 15 exon-deleted ER β splice variant tested, the results of our study clearly suggest that ER β and most of its splice variants do not act as tumor suppressors in human endometrium, but may have tumor-promoting properties.

ER β 1, 2 and 5 are known to be differentially expressed in hormone-dependent cancer (1-4). Whereas ER β 1 expression has been described to decline in breast and prostate cancer tissue, this effect seems not to be present in endometrial carcinoma (27-29). In line with previous studies, we did not observe altered ER β 1 transcript levels in endometrial cancer tissue (30,31). ER β 1 was also previously found not to be associated with the depth of myometrial invasion (31). With regard to ER β 2, some reports demonstrated a decline of this variant in endometrial cancer (31), whereas others found this receptor variant not to be altered in endometrioid cancer tissue (30). Our results are in line with the latter report and these findings may be supported by the fact that, in contrast to ER β 5, transcript levels of ER β 2 were not associated with proliferation markers. However, we found an unexpected, significant association of ER β 1, ER β 2 and 7 exon-skipped variants with HER2 receptor tyrosine kinase. Increased HER2 levels in breast and ovarian cancer as well as in different other malignancies have been

reported previously (32) and are associated with accelerated tumor progression (32). Accordingly, we detected an overexpression of HER2 in endometrial cancer tissue compared to normal endometrial tissue. Given that expression of HER2 is associated with an aggressive tumor phenotype (33,34), its association with ER β 1, ER β 2 and 7 further variants might be another argument against a protective role of ER β in endometrioid cancer (35). Our observation is in accordance with previous studies reporting association of ER β 1 with HER2 in breast cancer (36-38).

However, in other studies, expression of ER β 5 was reported to be unchanged or to be elevated in endometrial cancer tissue (30,39). Our study observing elevated ER β 5 mRNA levels in endometrial cancer, particularly in G3 tumors, is in line with the latter study and with reports from breast and prostate tissue (28,30,40). The demonstrated association of ER β 5 and 5 exon-skipped isoforms with the oncogene and cell cycle promoter MYBL2 (B-MYB) suggests that these ER β variants may be involved in tumor growth. The results of our ER β knockdown study employing the endometrial adenocarcinoma cell line HEC-1A not only corroborate these correlation data, but clearly suggest that MYBL2 transcript levels may be regulated by ER β variants in this cell line. MYBL2 is a transcription factor of the MYB family, which is amplified and overexpressed in many tumor types like breast or prostate cancer (41,42). It is proposed that MYBL2 is involved in controlling cell proliferation and differentiation (43-46). Our data showing increased levels of the MYBL2 gene in premenopausal tissue support the relevance of this gene in endometrial proliferation.

Transcript levels of 6 exon-skipped ER β variants were positively correlated with cyclin expression, again suggesting that ER β isoforms are associated with proliferation of endometrial cancer. Upregulated expression of cyclin B1 (47), cyclin D1 (48-54) and cyclin A2 (55) in endometrial carcinomas as well as various other cancer types have been previously reported (56). Furthermore, cyclin B1, D1 and A2 have been found to be associated with high levels of Ki-67, indicating their implication in cell proliferation and progression of endometrial cancer (57-59).

Our data suggest a role of ER β and its splice variants in endometrioid endometrial cancer. Whereas levels of ER β 1 and 2 were not altered in endometrial cancer tissue, the common ER β variant 5 was overexpressed in endometrial cancer. The significant increase of four ER β splice variants in cancer tissue and in G3 tumors and particularly the association of ER β isoforms with the oncogenes MYBL2 or HER2 suggest that ER β may be involved in the growth of endometrial cancer. These correlation data were corroborated by the results of our RNAi study establishing a direct link between ER β and MYBL2 expression.

Acknowledgements

We thank Helena Lowack for expert technical assistance.

References

1. Younes M and Honma N: Estrogen receptor β . *Arch Pathol Lab Med* 135: 63-66, 2011.
2. Leung YK, Mak P, Hassan S and Ho SM: Estrogen receptor (ER)- β isoforms: a key to understanding ER- β signaling. *Proc Natl Acad Sci USA* 103: 13162-13167, 2006.

3. Lewandowski S, Kalita K and Kaczmarek L: Estrogen receptor β . Potential functional significance of a variety of mRNA isoforms. *FEBS Lett* 524: 1-5, 2002.
4. Peng B, Lu B, Leygue E and Murphy LC: Putative functional characteristics of human estrogen receptor- β isoforms. *J Mol Endocrinol* 30: 13-29, 2003.
5. Poola I, Abraham J and Baldwin K: Identification of ten exon deleted ER β mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor β mRNA is distinct from that of estrogen receptor α . *FEBS Lett* 516: 133-138, 2002.
6. Cirisano FD and Karlan BY: The role of the HER-2/neu oncogene in gynecologic cancers. *J Soc Gynecol Investig* 3: 99-105, 1996.
7. Tsuda H, Hashiguchi Y, Inoue T and Yamamoto K: Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. *Oncology* 65: 159-166, 2003.
8. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
9. Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP and Saunders PT: Wild-type estrogen receptor (ER β 1) and the splice variant (ER β cx/ β 2) are both expressed within the human endometrium throughout the normal menstrual cycle. *J Clin Endocrinol Metab* 87: 5265-5273, 2002.
10. Matsuzaki S, Uehara S, Murakami T, Fujiwara J, Funato T and Okamura K: Quantitative analysis of estrogen receptor alpha and beta messenger ribonucleic acid levels in normal endometrium and ovarian endometriotic cysts using a real-time reverse transcription-polymerase chain reaction assay. *Fertil Steril* 74: 753-759, 2000.
11. Matsuzaki S, Fukaya T, Suzuki T, Murakami T, Sasano H and Yajima A: Oestrogen receptor α and β mRNA expression in human endometrium throughout the menstrual cycle. *Mol Hum Reprod* 5: 559-564, 1999.
12. Brandenberger AW, Lebovic DI, Tee MK, Ryan IP, Tseng JF, Jaffe RB and Taylor RN: Oestrogen receptor (ER)- α and ER- β isoforms in normal endometrial and endometriosis derived stromal cells. *Mol Hum Reprod* 5: 651-655, 1999.
13. Utsunomiya H, Suzuki T, Harada N, Ito K, Matsuzaki S, Konno R, Sato S, Yajima A and Sasano H: Analysis of estrogen receptor α and β in endometrial carcinomas: correlation with ER β and clinicopathologic findings in 45 cases. *Int J Gynecol Pathol* 19: 335-334, 2000.
14. Zhao C, Dahlman-Wright K and Gustafsson JA: Estrogen receptor β : an overview and update. *Nucl Recept Signal* 6: e003, 2008.
15. Treeck O, Lattrich D, Springwald A and Ortmann O: Estrogen receptor β exerts growth-inhibitory effects on human mammary epithelial cells. *Breast Cancer Res Treat* 120: 557-565, 2010.
16. Morani A, Warner M and Gustafsson JA: Biological functions and clinical implications of estrogen receptors α and β in epithelial tissues. *J Intern Med* 264: 128-142, 2008.
17. Leygue E, Dotzlaw H, Watson P and Murphy L: Altered estrogen receptor α and β mRNA expression during human breast tumorigenesis. *Cancer Res* 58: 3197-3201, 1998.
18. Iwao K, Miyoshi Y, Egawa C, Ikeda N and Noguchi S: Quantitative analysis of estrogen receptor- β mRNA and its variants in human breast cancers. *Int J Cancer* 88: 733-736, 2000.
19. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P and Rochefort H: Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumours. *Cancer Res* 61: 2537-2541, 2001.
20. Cai HB, Zhou YF, Wang BC and Gong LL: Expression of estrogen receptors α and β protein in endometrial carcinoma. *Cancer Therapy* 6: 907-912, 2008.
21. Šmuc T and Ržner T: Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. *Mol Cell Endocrinol* 301: 74-82, 2009.
22. Hu K, Zhong G and He F: Expression of estrogen receptors ER α and ER β in endometrial hyperplasia and adenocarcinoma. *Int J Gynecol Cancer* 15: 537-541, 2005.
23. Fujimoto J, Sakaguchi H, Aoki I, Toyoki I and Tamaya T: Clinical implications of the expression of estrogen receptor- α and - β in primary and metastatic lesions of uterine endometrial cancers. *Oncology* 62: 269-277, 2002.
24. Mylonas I, Jeschke U, Shabani N, Kuhn C, Kriegel S, Kupka MS and Friese K: Normal and malignant human endometrium express immunohistochemically estrogen receptor α (ER- α), estrogen receptor β (ER- β) and progesterone receptor (PR). *Anticancer Res* 25: 1679-1686, 2005.
25. Takama F, Kanuma T, Wang D, Kagami I and Mizunuma H: Oestrogen receptor β expression and depth of myometrial invasion in human endometrial cancer. *Br J Cancer* 84: 545-549, 2001.
26. Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H and Hollema H: Expression of estrogen receptor- α and - β and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. *Gynecol Oncol* 112: 537-542, 2009.
27. Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R and Ortmann O: Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. *Breast Cancer Res Treat* 110: 507-520, 2008.
28. Legue E, Dotslaw H, Watson PH and Murphy LC: Expression of estrogen receptor β 1, β 2 and β 5 messenger RNAs in human breast tissues. *Cancer Res* 59: 1175-1179, 1999.
29. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP and Speirs V: Nuclear and cytoplasmic expression of ER β 1, ER β 2 and ER β 5 identifies distinct prognostic outcome for breast cancer patients. *Clin Cancer Res* 14: 5228-5235, 2008.
30. Skrzypczak M, Bieche I, Szymczak S, Tozlu S, Lewandowski S, Girault I, Radwanska K, Szczylik C, Jakowicki JA, Lidereau R and Kaczmarek L: Evaluation of mRNA expression of estrogen receptor β and its isoforms in human normal and neoplastic endometrium. *Int J Cancer* 110: 783-787, 2004.
31. Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Rajwanshi A and Majumdar S: Estrogen receptor β 1 and the β 2/ β cx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. *Int J Gynecol Cancer* 17: 905-913, 2007.
32. Scholl S, Beuzebec P and Pouillart P: Targeting HER2 in other tumor types. *Ann Oncol* 12 (Suppl 1): S81-S87, 2001.
33. Berchuk A and Boyd J: Molecular basis of endometrial cancer. *Cancer* 76: 2034-2040, 1995.
34. Samarathai N, Hall K and Yeh IT: Molecular profiling of endometrial malignancies. *Obstet Gynecol Int* 2010: 162363, 2010.
35. Ejskjaer K, Sørensen BS, Poulsen SS, Forman A, Nexø E and Mogensen O: Expression of the epidermal growth factor system in endometrioid endometrial cancer. *Gynecol Oncol* 104: 158-167, 2007.
36. Umekita Y, Souda M, Ohi Y, Sagara Y, Rai Y, Takahama T and Yoshida H: Expression of wild-type estrogen receptor β protein in human breast cancer: specific correlation with HER2/neu overexpression. *Pathol Int* 56: 423-427, 2006.
37. Choi Y and Pinto M: Estrogen receptor β in breast cancer: associations between ER β , hormonal receptors, and other prognostic biomarkers. *Appl Immunohistochem Mol Morphol* 13: 19-24, 2005.
38. Lattrich C, Juhasz-Boess I, Ortmann O and Treeck O: Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor β 1. *Oncol Rep* 19: 811-817, 2008.
39. Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN and Saunders PT: Expression of oestrogen receptors, ER α , ER β , and ER β variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ER α . *BMC Cancer* 9: 330, 2009.
40. Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL and Ho SM: Estrogen receptor β 2 and β 5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. *Endocr Relat Cancer* 17: 675-689, 2010.
41. Sala A: MYBL2, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. *Eur J Cancer* 41: 2479-2484, 2005.
42. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC and Perou CM: In vitro and in vivo analysis of MYBL2 in basal-like breast cancer. *Oncogene* 28: 742-751, 2009.
43. Sala A and Calabretta B: Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. *Proc Natl Acad Sci USA* 89: 10415-10419, 1992.
44. Raschella G, Negroni A, Sala A, Pucci S, Romeo A and Calabretta B: Requirement of b-myb function for survival and differentiative potential of human neuroblastoma cells. *J Biol Chem* 270: 8540-8545, 1995.
45. Sala A, Casella I, Bellon T, Calabretta B, Watson RJ and Peschle C: B-myb promotes S phase and is a downstream target of the negative regulator p107 in human cells. *J Biol Chem* 271: 9363-9367, 1996.
46. Seong HA, Manoharan R and Ha H: MYBL2 positively regulates serine-threonine kinase receptor-associated protein (STRAP) activity through direct interaction. *J Biol Chem* 286: 7439-7456, 2011.

47. Tang L, Zhang Y, Pan H, Luo Q, Zhu XM, Dong MY, Leung PC, Sheng JZ and Huang HF: Involvement of cyclin B1 in progesterone-mediated cell growth inhibition, G2/M cell cycle arrest, and apoptosis in human endometrial cell. *Reprod Biol Endocrinol* 7: 144, 2009.
48. Arnold A and Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. *J Clin Oncol* 23: 4215-4224, 2005.
49. Barbieri F, Cagnoli M, Ragni N, Foglia G, Bruzzo C, Pedullà F and Alama A: Increased cyclin-D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. *Clin Cancer Res* 5: 1837-1842, 1999.
50. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG and Korc M: Increased cyclin-D1 in human pancreatic cancer is associated with decreased postoperative survival. *Oncology* 55: 363-369, 1998.
51. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, Schmidt EV and Arnold A: Cyclin-D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin-D1 oncogene. *Mod Pathol* 8: 560-567, 1995.
52. Ito K, Sasano H, Yoshida Y, Sato S and Yajima A: Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma. *Anticancer Res* 18: 1661-1664, 1998.
53. Nikaïdo T, Li SF, Shiozawa T and Fujii S: Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. *Cancer* 78: 1248-1253, 1996.
54. Özuysal S, Öztürk H, Bilgin T and Filiz G: Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. *Arch Gynecol Obstet* 271: 123-126, 2005.
55. Yam CH, Fung TK and Poon RYC: Cyclin A in cell cycle control and cancer. *Cell Mol Life Sci* 59: 1317-1326, 2002.
56. Milde-Langosch K, Bamberger AM, Goemann C, Rössing E, Rieck G, Kelp B and Löning T: Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. *J Cancer Res Clin Oncol* 127: 537-544, 2001.
57. Nishimura Y, Watanabe J, Jobo T, Kato N, Fujisawa T, Kamata Y and Kuramoto H: Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. *Anticancer Res* 24: 2185-2191, 2004.
58. Sivridis E and Giatromanolaki A: The pathogenesis of endometrial carcinomas at menopause: facts and figures. *J Clin Pathol* 64: 553-560, 2011.
59. Yasumizu T, Ogawa K and Kato J: Comparison of the clinicopathological characteristics of premenopausal and postmenopausal endometrial carcinomas: analysis of endocrinologically evaluated cases. *Jpn J Clin Oncol* 26: 152-156, 1996.
60. Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC Jr and Harris HA: Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor- β ligands. *J Med Chem* 47: 5021-5040, 2004.
61. Minutolo F, Bertini S, Granchi C, Marchitello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther JR, Carlson KE, Katzenellenbogen JA and Macchia M: Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor β . *J Med Chem* 52: 858-867, 2009.